News

Public · Published

UBS maintains Axsome Therapeutics at Buy, lowers price target to $239 from $256

UBS kept its Buy rating on Axsome Therapeutics but lowered its price target to $239 from $256, a 6.6% decrease. The new target implies 75.7% upside from the November 2 close of $136.01.

Published:

Updated:

What happened

UBS kept its Buy rating on Axsome Therapeutics but lowered its price target to $239 from $256, a 6.6% decrease. The new target implies 75.7% upside from the November 2 close of $136.01.

Confirmed

Global impact / market context

A lower target still signals analysts expect big gains, so UBS likely trimmed expectations rather than lost confidence. Because analyst targets guide how investors weigh future revenue and spending on drug development, even small cuts can shift buying and selling decisions.

Analyst inference

Other recent notes set targets from $220 to $273, so UBS sits near the middle of that range. The spread shows analysts agree on direction but differ on how much the company's pipeline, which means its experimental drugs, is worth today.

Analyst inference

What to watch

  1. The other recent targets run from $220 to $273, so watch whether more firms trim rather than raise their targets. Confirmed
  2. Watch whether UBS later changes its Buy rating, since a downgrade would be a stronger signal than a lower target. Proposed
  3. Watch upcoming company updates on drug trials and sales, because those results drive whether analyst targets rise or fall. Analyst inference

Evidence

  • Original source link unavailable